Page last updated: 2024-09-04

butyryl-n-trihexylcitrate and Coronary Restenosis

butyryl-n-trihexylcitrate has been researched along with Coronary Restenosis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almalla, M; Burgmaier, M; Reith, S; Schröder, J; Vogt, F1
Bruno, H; Erglis, A; Graf, K; Hehrlein, C; Hoffman, S; Kornowski, R; Merkely, B; Naber, C; Richardt, G; Slagboom, T; Toelg, R; Witzenbichler, B1

Other Studies

2 other study(ies) available for butyryl-n-trihexylcitrate and Coronary Restenosis

ArticleYear
Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons.
    Coronary artery disease, 2018, Volume: 29, Issue:8

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Butyrates; Cardiac Catheters; Cardiovascular Agents; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Equipment Design; Excipients; Female; Humans; Iohexol; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome

2018
Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Butyrates; Coronary Restenosis; Excipients; Female; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Registries

2014